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Clinical relevance  
Obesity can lead to a myriad of health complications, including non-alcoholic fatty liver disease, low-
grade inflammation and insulin resistance. Yet the early molecular mechanisms that underlie the 
development of the health complications remain incompletely understood, and studies of human 
obesity are often confounded by the complexity of contributing genetic and environmental factors. 
Here, we aimed to elucidate the early alterations in the plasma proteome associated with excess 
body weight independently of genetic factors, by studying a unique cohort of monozygotic twin pairs 
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discordant for BMI. Subgroup analysis of pairs discordant and concordant for liver fat was used to 
assess the effect of liver fat, indicative of progression towards metabolic complications. Our plasma 
proteomics data demonstrated that aberrant complement activation and inflammation associate 
with excess body weight in clinically healthy individuals, independently of genetic factors or liver fat. 
The findings suggest that systemic complement dysregulation and inflammation, previously linked to 
obesity-related complications, are very early events in obesity. Thus, countering them could be 
protective against metabolic complications and help preserve metabolic health. 
 
Abstract  
Purpose. The purpose of this study was to elucidate the effect of excess body weight and liver fat on 
the plasma proteome without interference from genetic variation. 
Experimental design. The effect of excess body weight was assessed in young, healthy monozygotic 
twins from pairs discordant for body mass index (intrapair difference (Δ) in BMI > 3 kg/m2, n=26) 
with untargeted LC-MS proteomics quantification. The effect of liver fat was interrogated via 
subgroup analysis of the BMI-discordant twin cohort: liver fat discordant pairs (Δliver fat > 2%, n=12) 
and liver fat concordant pairs (Δliver fat < 2%, n=14), measured by magnetic resonance 
spectroscopy.  
Results. 75 proteins were differentially expressed within the BMI-discordant pairs, with significant 
enrichment for complement and inflammatory response pathways in the heavier co-twins. The 
complement dysregulation was found in obesity in both the liver fat subgroups. The complement 
and inflammatory proteins were significantly associated with adiposity measures, insulin resistance 
and impaired lipids.  
Conclusions and clinical relevance. The early pathophysiological mechanisms in obesity are 
incompletely understood. We showed that aberrant complement regulation in plasma is present in 
very early stages of clinically healthy obese persons, independently of liver fat and in the absence of 
genetic variation that typically confounds human studies. 
Introduction 
Obesity is an intractable major public health burden, affecting, along with overweight, close 
to 40% of the world’s population [1]. While obesity is frequently associated with metabolic 
abnormalities, such as insulin resistance, type 2 diabetes and cardiovascular diseases [2], 
development of the concomitant diseases varies widely, and a notable subgroup of subjects with 
obesity especially during younger ages appears to be metabolically healthy [3] [4]. Even though the 
detailed mechanisms underlying such phenomena are not fully understood, some data suggest that 
ectopic fat deposition to the liver is a contributing factor to the development of metabolic 
abnormalities, since healthier and insulin sensitive individuals, despite obesity, have less liver fat [5] 
[6] [7] [8]. Thus, improved characterization of the early molecular alterations in obesity, which may 
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contribute to the metabolic derangements, perhaps through liver fat accumulation, is pivotal for 
facilitating the development of more effective, targeted approaches for their treatment and 
prevention.  
Elucidation of underlying molecular pathways requires global quantitative methods. MS-
based proteomics is ideal for identification and quantification of protein level differences in a system 
and offer a detailed characterization of metabolism in healthy versus diseased states. As proteins 
provide a broad picture of patient phenotype [9] [10], proteomics discovery approach can be used to 
discover the molecular malfunctions related to diseases and their progression in individual patients. 
Accessibility and the extensive potential to reflect metabolic state [9] [11] [12] [13] makes human blood 
plasma and serum the predominant source material for clinical analyses. However, there appears to 
be a surprising paucity of data in the literature characterizing the effect of obesity on the global 
proteome of human plasma. This could be in part explained through the high dynamic range of 
plasma, which impedes the identification of more than a few hundred of the most abundant 
proteins by liquid chromatography mass spectrometry (LC-MS). However, depletion of highly 
abundant plasma proteins can partially overcome this issue [14]. The few published studies reported 
variable global protein alterations in plasma or peripheral blood mononuclear cells of individuals 
with obesity, and mostly highlighted proteins of either the complement cascade or immune system 
as upregulated in obesity [15] [16] [17] [18].  
Genetics, multiple environmental factors, age and sex may play a role in an individual’s 
metabolic and plasma proteomic response to obesity. Indeed, human plasma proteomic signatures 
can be highly variable between individuals [14] [18]. To this end, we used in the present study a rare 
monozygotic (MZ) twin-pair design where the co-twins are discordant for body mass index (BMI), 
which uniquely enables the control for genetic background, early development and environment, 
age and sex between heavy and lean individuals. We characterized obesity-related human plasma 
proteomic changes through MS-based proteomics analysis, after depleting the 12 highly abundant 
plasma proteins. First, we compared the proteomics profiles within all the BMI-discordant twin pairs 
and then, to assess the particular role of ectopic accumulation of fat to the liver on plasma 
proteomics, we further divided the twin pairs into those who were discordant or concordant for liver 
fat and analyzed the within-pair proteomics differences in these subgroups. We hypothesized that 
BMI-discordance with liver fat discordance results in a metabolically more disadvantaged plasma 
proteome than BMI-discordance without liver fat discordance. We also analyzed the overall 
associations between plasma proteins and other adiposity measurements, lipids and insulin 
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resistance, with the aim to find the proteins most closely correlating with metabolic disturbances in 
obesity.  
 
Materials and methods 
Participants 
The present study included 26 rare monozygotic (MZ) pairs discordant for BMI (within-pair 
difference, ΔBMI ≥3 kg/m2), identified from two population-based twin cohorts, FinnTwin16 (n = 
2839 pairs) and FinnTwin12 (n = 2578 pairs) [19]. One obese co-twin had type 2 diabetes and used 
metformin and insulin. Another obese co-twin had inactive ulcerative colitis and used mesalazine 
and azathioprine. All other participants were healthy, normotensive and did not use any medications 
except for oral contraceptives. Detailed descriptions of the twin material have been previously 
published [8] [20] [21].  Written informed consent was obtained from all participants. The study 
protocols were approved by the Ethical Committee of the Helsinki University Central Hospital (DNRO 
270/13/03/01/2008). 
 
Clinical measurements 
Weight and height were measured for the calculation of body mass index (BMI). Body composition 
was determined by dual-energy X-ray absorptiometry (Lunar Prodigy, Madison, WI, software version 
8.8) [22], the amount of subcutaneous and intra-abdominal adipose tissue by magnetic resonance 
imaging (MRI)[23] and liver fat by proton magnetic resonance spectroscopy with a 1.5 Tesla MRI 
imager (Avanto, Siemens, Erlangen Germany) [20].  
Dietary intake was assessed from 3-day food records and analyzed by the Diet32 program (Aivo), 
based on a national Finnish database for food composition (Fineli, www.fineli.fi, National Institute 
for Health and Welfare, Nutrition Unit, Helsinki, Finland). Information on weekly alcohol intake 
during the past 4 weeks was obtained by structured questionnaires and total physical activity by the 
Baecke questionnaire and transformed into number of standard drinks (12 grams of alcohol per 
drink) per week and total physical activity by the Baecke questionnaire [24].  
Analytical measurements 
The concentrations of fasting plasma glucose, insulin during a 2-hour oral glucose tolerance test, and 
homeostatic model assessment (HOMA)-insulin resistance and Matsuda insulin sensitivity indexes 
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were calculated, as previously described [25]. Fasting serum high sensitivity C-reactive protein (hsCRP) 
was measured by Cobas CRP [Latex]HS (Roche Diagnostics). Fasting plasma total cholesterol, high- 
(HDL) and low-density lipoprotein (LDL) cholesterol and triglyceride concentrations were determined 
with enzymatic methods (Abbott Architect c16000 and c8000, Abbott).  
Plasma proteomics 
Plasma samples from EDTA tubes, obtained after centrifugation for 15 min at 380×g, were used for 
proteomics analyses. Multiple affinity removal columns designed to remove high abundant plasma 
proteins. The workflow is described in detail [26]. Briefly, top 12 high-abundant proteins were 
depleted by TOP12 protein depletion kit (Pierce, ThermoFisher) according to the manufacturer's 
instructions. In order to make sure equal amounts of proteins from all samples were processed for 
digestion and to ensure downstream equal loading onto the LC-MS, the TOP 12 proteins depleted 
plasma was assayed by BCA assay kit (Pierce, Thermo Scientific, Rockform, IL, USA) for the total 
protein concentration. The depleted proteins were reduced and alkylated by incubating samples first 
in 10 mM of DTT for 60 minutes at room temperature (RT) followed by incubation in 40 mM 
iodoacetamide for 60 minutes in the dark at RT. Excess iodoacetamide was quenched by adding 
40mM DTT for 1 hour at RT. Later samples were diluted 1:10 with ultrapure water (Milli-Q, EMD 
Millipore corp.) and digested with trypsin (1:50 w:w trypsin to protein ratio) for overnight at +37˚C. 
Samples were cleaned by Pierce C18 columns (Pierce, ThermoFisher) according to the manufactures 
protocol. 
 
 
LC-MS and quantification 
Samples equivalent to ~1.4 μg total protein were injected to nano Acquity UPLC (Ultra Performance 
Liquid Chromatography) ‐ system (Waters Corporation, MA, USA). TRIZAIC nanoTile 85 μm × 100 mm 
HSS‐T3u wTRAP was used in the LC system before mass spectrometer. Samples were loaded, 
trapped and washed for two minutes with 8.0 μL/min with 1% B. The analytical gradient was as 
follows: 
0–1 min 1% B, at 2 min 5% B, at 65 min 30% B, at 78 min 50% B, at 80 min 85% B, at 83 min 85% B, at 
84 min 1% B and at 90 min 1% B with 450 nL/min. Buffer A: 0.1% formic acid in water and Buffer B: 
0.1% formic acid in acetonitrile. 
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DIA (data independent acquisition using HDMSE mode with Synapt G2‐S HDMS (Waters Corporation, 
MA, USA) was used for data acquisition. The collected data range was 100–2000 m/z, scan time one‐
second, IMS wave velocity 650 m/s and collision energy ramp was employed in trap between 20 and 
60 V. Calibration was done with Glu1‐Fibrinopeptide B MS2 fragments and as a lock mass, Glu1‐
Fibrinopeptide B precursor ion was used during the runs. Data was collected in triplicates for every 
sample and further analysis was done with, Progenesis QI for Proteomics – software (Nonlinear 
Dynamics, Newcastle, UK). 
Data analysis was performed essentially as previously described [26]. Briefly, the raw files were 
imported to Progenesis QI for proteomics software (Nonlinear Dynamics, Newcastle, UK). Lock mass 
correction with 785.8426 m/z, corresponding to doubly charged Glu1‐Fibrinopeptide B was 
employed. Parameters for peak picking and alignment algorithm were default in the software. The 
software performed the peptide identification with Protein Lynx Global Server and label‐free 
quantification [27] was used. The peptide identification was done against Uniprot human FASTA 
sequences (UniprotKB Release 2015_09, 20205 sequence entries) with peptides of CLPB form E. Coli 
(CLPB_ECOLI (P63285)) as an internal standard, ClpB protein sequence appended to FASTA file for 
label‐free quantification. Equal amount of pre-known mixture of CLPB peptides was added to each 
sample and post MS acquisition was used to normalize the raw intensities. Fixed modification at 
cysteine (carbamidomethyl) and variable at methionine (oxidation) was used. Trypsin was specified 
as digesting agent and one missed cleavage was allowed. Fragment and peptide error tolerances 
were set to auto and FDR to less than 4%. This is the maximum allowed FDR and in these settings the 
search stops when FDR reaches 4%. All peptides where the error was more than 10 ppm were 
deleted and not considered further for analysis. Minimum one fragment per peptide, three or more 
fragments per protein and one or more peptides per protein were required for ion matching which 
also happen to be default parameters. The identified proteins are grouped using parsimony principle 
and peptides unique to the protein are also reported. However, a strict parsimonious approach is 
not taken and more details can be found at the software website (www.nonlinear.com).   
Statistical analyses 
The statistical analyses were performed using Stata statistical software (release 15.0; Stata 
Corporation), R language and environment for statistical computing (version 3.4.1, R Core Team) and 
Python programming language (version 3.6.5, Python Software Foundation). Comparisons of the 
heavier vs leaner co-twins’ clinical measurements in the BMI-discordant groups were analyzed by 
paired t-tests and comparisons of the unrelated lean-lean and heavy-heavy co-twins and Δvalues 
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between pairs of liver fat discordant vs. liver fat concordant subgroups by unpaired t-tests. 
Differential proteomics analysis between co-twin groups were conducted on log10 normalized data 
using empirical Bayes approach presented in LIMMA  [28], with default settings. In short, the method 
relies on the analysis of the expression matrix where each row represents genomic feature, and each 
column corresponds to a sample of the given study. The linear modeling is performed on the 
expression matrix in the row-wise fashion, with both coefficients and standard errors for the 
comparison of interest. Once linear model is fitted coefficients are used to compute statistics for all 
genomic features using empirical Bayes moderation of the standard errors [29]. This approach was 
shown to be more robust compared to standard T-test, especially in settings with a small sample size 
[30]. We encourage interested users to read more detailed statistical discussion about empirical Bayes 
approach used by LIMMA elsewhere [28] . Correlation between proteins and clinical variables 
summed over all twin individuals (from concordant and discordant   pairs) were calculated by using 
Pearson correlation, corrected for age and sex and family relationship within the twin pairs as 
described by Price et al. [31]. All p values are reported after FDR correction (Benjamin-Hochberg) with 
significance level of 0.05. 
Pathway analyses 
Three different pathway analyses were performed for differentially expressed proteins (nominal p 
value < 0.05) between the co-twins. First, after the Gene ontology (GO) annotation for proteins 
detected was retrieved, the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
was used for functional annotation analysis including GO enrichment. Second, the Ingenuity Pathway 
Analysis (IPA), (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-
analysis) was applied. Third, the same dataset was applied to STRING version 10.5 (http://string-
db.org) in order to elucidate more details about protein–protein interactions and protein networks. 
Data availability 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE [32] partner repository with the dataset identifier PXD010691. 
Results and discussion 
Clinical characteristics 
The detailed clinical characteristics of the twins are presented in Table 1. In brief, and as 
published before [33] [34], the heavier co-twins of the BMI-discordant pairs (n= 26) weighed on 
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average 18 kg more, had significantly higher fat percentage and more subcutaneous, intra-
abdominal and liver fat, were more insulin resistant, and had higher LDL cholesterol and triglyceride 
and lower HDL cholesterol levels than the lean co-twins.  The BMI-discordant twin pairs were then 
further divided into liver fat discordant (n=12) and liver fat concordant (n=14) subgroups (median Δ
liver fat cut-off 2%), as described earlier [8] [35] (Figure S1). These subgroups were equally discordant 
for overall fatness, but the liver fat discordant group had significantly larger differences in intra-
abdominal fat, LDL cholesterol and hsCRP within pairs than the liver fat concordant group (Table 1). 
Also, the heavy co-twins of the liver fat discordant subgroup had significantly higher levels of liver 
fat, intra-abdominal adipose tissue and insulin resistance than the heavy co-twins of the liver fat 
concordant group. In lifestyle questionnaires, the heavy co-twins of the liver fat discordant group 
reported more alcohol consumption and less physical activity than their lean counterparts, which 
may have contributed to the higher liver fat content. No significant lifestyle differences were 
observed within the liver fat concordant group. 
Comparison of plasma proteome profiles between the co-twins 
To elucidate the biological impact of acquired excess body weight on the plasma proteome, 
we first compared the co-twins in all of the 26 BMI-discordant MZ twin pairs. Across the individuals, 
we identified and quantified 469 plasma proteins, of which 75 proteins were significantly altered 
within the BMI-discordant pairs (nominal p < 0.05) (Table 2). Of these, 19 were downregulated and 
56 were upregulated in the heavy compared with lean co-twins. Many of the identified proteins are 
previously reported markers for obesity, e.g. increased circulating levels of apolipoprotein B-100 
(APOB) [36],  complement component 3 (C3) [37],  and serum amyloid A1 protein [18] [38] [39], validating 
our study model and method. 
Next, we investigated the contribution of acquired liver fat on the plasma proteome by 
analyzing within-pair differences in the liver fat discordant and concordant groups separately. In the 
liver fat discordant pairs, we detected 31 significantly altered proteins; of these 12 were 
downregulated and 29 upregulated in the heavy as compared with lean co-twins. In the liver fat 
concordant pairs, 64 proteins were significantly altered, 15 and 49 were down- and upregulated, 
respectively, in the heavy co-twins (Tables S1- S4). It is perhaps surprising that more significantly 
altered proteins were detected in the liver fat concordant subgroup. As liver fat accumulation has 
been previously shown to be a marker of progression towards metabolically unhealthy obesity, we 
hypothesized the liver fat discordant twins to differ more significantly for plasma proteome profiles. 
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However, based on the results of our study, it does not seem that liver fat discordance produces 
larger differences to the plasma proteome than liver fat concordance, as we hypothesized initially.  
There were 5 common proteins significantly differentially expressed between the co-twins in 
both the liver fat subgroups (Figure 1A, B), all of which were up-regulated in the heavy co-twins 
(Figure 1B). Interestingly, these were up-regulated in the entire group of BMI-discordant pairs (n=26) 
as well. This may suggest their putative function in obesity in general, at very early obesity stages 
and irrespective of the liver fat status. Of these 5 proteins, APOB is the primary protein in LDL 
cholesterol, a key feature of dyslipidemia and cardiovascular disease [36]. Coagulation factor VII has 
been found to be increased in obesity and metabolic syndrome previously [40] [41]. Complement 
component 4B (C4B) and complement factor H-related protein 5 (CFHR5) are proteins from the 
complement pathway of the innate immune system, and C4B was reported as increased in the 
serum of obese individuals [16]. Potential link of nuclear pore complex protein Nup107 to obesity is at 
present unknown. However, its’ circulating levels have previously been upregulated in severe 
infections [42]. 
Pathway analysis of the significantly altered proteins between the co-twins  
To construct an overall understanding of how the differentially expressed proteins are linked 
to each other, and to identify enriched functional annotation terms within the datasets, we applied 
protein pathway analysis. First, all the 75 statistically significantly modified proteins in plasma from 
all BMI-discordant co-twins were analyzed in DAVID, which identified 18 significant clusters in GO (p 
value < 0.05, enrichment score > 1.3). Interestingly, all of the top 5 biological processes were related 
to the immune system. The complement system was particularly over-represented (Figure 2A), and 
based on the direction of differential expression, overactivated in the heavy co-twins. In line with 
our DAVID analysis, the complement system and inflammation were among the top 5 enriched 
canonical pathways in the IPA (Figure 2B) and in the STRING pathway analyses (Figure 2C). The 
complement system has been linked to either obesity or weight loss in previous serum proteomics 
studies as well [16] [18] [43]. 
STRING, DAVID, and IPA pathway analysis within liver fat concordant subgroup also 
identified complement activation and humoral immune response (Figure S2). Despite the fewer 
enriched pathways in liver fat discordant subgroup, the complement and coagulation pathways were 
still enriched, demonstrating that on the pathway level the alterations in the plasma proteomic 
profiles between the co-twins are similar between the subgroups (Figure S2). This may be an 
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indication that aberrant regulation of these pathways is a very early event in obesity that is 
independent of liver fat and perhaps precedes the accumulation of fat into the liver. 
Interconnections between the significantly altered proteins and correlations between proteins in 
the top proteome pathways and the clinical characteristics  
Because of the similarities in the pathways in both subgroups, we focused further analyses 
to the entire study group of 26 twin pairs. To visualize the interactions and relationships of proteins 
we synthesized a network in STRING that was built from 75 significantly altered proteins (Figure 3). 
The proteins in the top 2 STRING pathways, complement activation and regulation of inflammatory 
response, were highly interconnected, indicating a coordinated regulation of these pathways as a 
result of acquired excess body weight. 
We then selected all complement and inflammatory related proteins (based on their 
molecular and biological functions derived from Uniprot, Table 2) amongst the 75 significantly 
altered proteins (Table 2) for further investigation on how they correlate with clinical adiposity and 
metabolic parameters on the individual level (Figure 4). Most of the significantly altered 
complement proteins correlated significantly positively with BMI (6/10 proteins), subcutaneous fat 
(5/10), intra-abdominal fat (5/10), and liver fat (5/10), and negatively with HDL (8/10). In line with 
previous studies, complement factor H (CFH) levels correlated significantly with insulin resistance [37] 
[44] [45]. Further, both C3 and CFH correlated positively with liver fat. Interestingly, CFHR5 exhibited 
equally strong positive correlations with BMI and adiposity measurements and LDL, and a negative 
correlation with HDL cholesterol. CFHR5 was one the five proteins differentially expressed between 
the co-twins in all three study groups (all BMI-discordant as well as both the liver fat subgroups), 
which together with the correlation analysis, supports CFHR5 as a prospective biomarker for obesity 
with potential connections to dyslipidemia. In addition, CFHR5 inactivates C3b via binding to CRP [46].  
The correlations of the complement cascade proteins with the clinical measurements were 
overall stronger than for the inflammatory response related proteins (Figure 4). Most complement 
proteins correlated positively with adiposity and insulin resistance, and negatively with HDL 
cholesterol – similar to previously published findings [33]. Of the inflammatory-related proteins, S100-
A9 correlated positively with adiposity measures, while lipopolysaccharide-binding protein (LPS) 
correlated positively with adiposity measurements and negatively with insulin sensitivity, 
corroborating previous reports [47] [48] [49]. OTU domain-binding protein 7B, an activator of the 
growth-promoting mTORC2 pathway [50], previously found to be a marker candidate for early 
myocardial injury in plasma [51]and inhibitor of the non-canonical NF-kB pathway [52], correlated 
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positively with adiposity measurements, and negatively with HDL. HLA class II histocompatibility 
antigen also correlated positively with liver fat and LDL. In line with this, we previously reported in 
another set of obesity-discordant MZ twin pairs a significant overexpression of major 
histocompatibility class II molecules in adipose tissue of the heavier co-twins [53], suggesting a role of 
adipocytes as antigen-presenting cells in the generation of the adaptive pro-inflammatory immune 
response in obesity [54]. CFH from the complement cascade proteins and serum amyloid A1 from the 
inflammatory response proteins showed the strongest positive correlation with hsCRP. 
Putative effects of the significantly altered complement proteins between the co-twins for the 
complement cascade activity 
Taken together with the fact that the complement activation was the most robustly 
identified pathway in our analyses and clearly correlated with measurements of metabolic health, 
we next aimed to derive insight into what functional effects the significantly altered proteins might 
reflect by mapping their positions and inspecting their functions within the complement cascade 
(Figure 5).  
The complement system is an integral part of the immune system that is increasingly 
recognized as a pathogenic mechanism in metabolically important tissues including adipose tissue, 
liver and pancreas [55]. Complement activation can be divided into stages: Initiation through one of 
the three pathways (the classical, mannose-binding lectin or alternative pathway) leads to the 
formation of C3 convertases (Figure 5). At this stage, the initiation from any of the three pathways 
can be escalated through the amplification loop of the alternative pathway. Active C3 convertase 
results in the formation of C5 convertases, which propagate inflammation and initiate the terminal 
pathway culminating in the formation of membrane attack complex and cell lysis. A number of 
factors can inhibit the complement system to protect host tissues from complement driven damage 
and inflammation. In the heavier co-twins, the plasma levels of the cascade initiating proteins, and a 
subunit of the C3 and C5 convertases of the classical and mannose-binding lectin pathways, were 
increased. Additionally, the level of C3, was increased (Figure 5). The alternative pathway and the 
amplification loop appeared to be actively suppressed through increased levels of inhibitory proteins 
(CFH, CFI). Components of the terminal complement pathway (C8 and vitronectin) responsible for 
forming the membrane attack complex were also increased.  
These findings are well in line with previous studies of serum and plasma showing obesity-
related upregulation of the complement cascade [16] [18] [56] [57], with sexual dimorphism [17] [58], and in 
part reminiscent of our own previous study focusing on the complement system in the adipose 
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tissue in the same cohort of BMI-discordant monozygotic twins [33]. A similar pattern of increase in 
the classical initiation pathway (C1q), C3 and active suppression of the alternative pathway (CFH, 
CFI) is seen between the plasma proteome and adipose tissue transcriptome in the heavier co-twins 
(Figure 5, [33]). This observation suggests that these proteins in the plasma could be reflective of the 
adipose tissue status, although we acknowledge that our study set up does not allow for direct 
assessment of the origin of the circulating proteins. In contrast, the terminal pathway was either 
unaltered (C7-9) or downregulated (C6) in the adipose tissue [33], while the protein levels of two C8 
subunits were increased in the plasma, indicative that these may reflect complement-related 
processes in other tissues.    
Interestingly, the protein levels of plasma protease C1 inhibitor (an inhibitor of the classical 
initiation pathway) and vitronectin (an inhibitor of the terminal pathway [59]) were also increased in 
the heavier co-twins’ plasma. Combined with the active inhibition of the amplification loop 
demonstrated by us and others [43], the increase in these inhibitory regulators could be suggestive of 
a wider protective mechanism acting to protect host cells and tissues from the aberrantly activated 
complement system, over inflammation and cell lysis.  
Concluding remarks 
In the present study we used a unique study set-up of BMI-discordant MZ twins to profile 
the effects of excess body weight on the plasma proteome. We demonstrated that obesity is 
associated with increased levels of proteins in the complement system and inflammatory response 
pathways, even in the absence of interference from genetic differences. Overall, our findings are in 
line with previous studies, especially the ones where plasma proteomics profiles in obesity were 
shown to be characterized by complement activation [15] [16] [17]. However, as our results are derived 
from the MZ co-twin control design, we were able to exclude the effects of heritable factors as 
determinants of the large interindividual variation of the plasma proteome [60], and of proteins in the 
immune [12] or the complement systems [61]. Our study highlights that complement and inflammatory 
proteins associate significantly with higher levels of adiposity, insulin resistance, LDL cholesterol and 
hsCRP as well as with lower levels of HDL cholesterol. However, although these proteomics profiles 
were generally following increases in all adiposity measures, they were not specific for liver fat.  
The main limitation of our study was the small study sample (due to the extreme rarity of 
young adult healthy BMI-discordant MZ twin pairs), which resulted in a limited statistical power to 
identify proteins significantly differentially expressed proteins with adjusted p value or proteins 
specific to the accumulation of fat into the liver. While proteins with nominal significance were 
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included in the pathway analyses, we used three independent pathway analyzers as a way to verify 
the results, all of which consistently showed the complement cascade as a significantly altered 
pathway in obesity. The similarity of the pathway level findings in the liver fat subgroups was useful 
to demonstrate that the alterations in the complement pathway appear to be a very early 
phenomenon that precedes the detrimental ectopic fat deposition in the liver. Identifying these 
early events in the pathophysiology of obesity is integral to further our understanding of how 
healthy obesity progresses to unhealthy obesity and metabolic disease. Moreover, it should be 
noted that even the obese co-twins (with the exception of the one co-twin with type 2 diabetes) are 
considered metabolically healthy, and therefore assessments of the entire cohort are still highly 
informative with regard to the early molecular level changes associated with excessive body weight. 
In conclusion, our findings suggest that complement dysregulation is a very early event in 
obesity. Furthermore, the increase in the inhibitory proteins acting on several different stages of the 
complement cascade could represent an endogenous protective adaptation against complement-
driven inflammation and tissue damage. Thus, bolstering the inhibition of complement activation is a 
promising treatment target to protect against metabolic complications and preserve metabolic 
health in obesity. 
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Table 1. The clinical characteristics of all BMI-discordant monozygotic twin pairs (n=26) and subdivisions in the liver fat discordant (n=12) and concordant 
(n=14) twin pairs. Data presented as mean (SD). 
  
All BMI-discordant pairs 
BMI-discordant, liver fat 
discordant pairs 
BMI-discordant, liver fat 
concordant pairs 
Comparisons between liver fat discordant vs. 
liver fat concordant groups 
Number of 
twin pairs 
26 12 14 
p value 
(Leaner vs 
Leaner)
a,b
 
p value 
(Heavier vs 
Heavier)
a, b
 
p value (Within-
pair differences)
a,b
 
Age range 22.8-37.0 22.8-36.1 24.1-37 0.8679 0.8679   
Sex (m/f) 9/17 6/6 3/11 0.127 0.127   
Clinical 
Parameters Le
an
e
r 
H
e
av
ie
r Within-Pair 
Le
an
e
r 
H
e
av
ie
r Within-Pair 
Le
an
e
r 
H
e
av
ie
r Within-Pair     
p value 
(Leaner vs 
Heavier)
c
 
p value 
(Leaner vs 
Heavier)
c
 
p value 
(Leaner vs 
Heavier)
c
 
      
Height (cm) 
172.5 
(11.1) 
172.8 
(10.8) 
0.2827 
173.1 
(11.3) 
173.4 
(11.1) 
0.5004 
171.9 
(11.2)  
172.3 
(11.0)  
0.4265 0.7850 0.7936 0.9066 
Weight (kg) 
74.9 
(17.9) 
92.6 
(20.0) 
<0.001 
77.4 
(18.7) 
98.1 
(20.9) 
<0.001 
72.7 
(17.6)  
87.9 
(18.7)  
<0.001 0.5051 0.2038 0.1254 
BMI (kg/m2) 
24.9 
(4.4) 
30.8 
(5.1) 
<0.001 
25.6 
(3.7) 
32.4 (4.8) <0.001 
24.4 
(5.0)  
29.4 
(5.1)  
<0.001 0.5147 0.1411 0.0930 
Body fat (%) 
31.1 
(10.1) 
40.7 
(7.2) 
<0.001 
29.0 
(11.2) 
39.0 (7.2) <0.001 
32.9 
(9.1)  
41.9 (7.2)  <0.001 0.3415 0.3444 0.6027 
Subcutaneous 
adipose 
tissue (cm3) 
3587.1 
(2120.5) 
6102.6 
(2758.7) 
<0.001 
3513.2 
(2209.5) 
6240.4 
(3332.49) 
<0.001 
3650.5 
(2122.9)  
5984.6 
(2281.9)  
<0.001 0.8731 0.8191 0.5398 
Intra-
abdominal 
adipose 
tissue (cm3) 
591.6 
(396.8) 
1387.1 
(770.9) 
<0.001 
623.8 
(350.1) 
1874.5 
(763.1) 
<0.001 
564.0 
(444.1)  
969.2 
(492.6)  
<0.001 0.7095 0.0013 <0.001 
Liver fat (%) 0.8 (0.9) 3.9 (4.0) 0.0006 1.0 (0.9) 7.3 (3.3) <0.001 0.7 (0.8) 0.9 (0.7) 0.1570 0.4731 <0.001 <0.001 
fP-glucose 5.1 (0.4) 5.4 (1.0) 0.1182 5.2 (0.5) 5.7 (1.4) 0.1590 5.0 (0.3) 5.1 (0.5) 0.5448 0.3224 0.1346 0.2211 
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(mmol/L) 
fS-insulin 
(mU/L) 
5.1 (2.9) 7.9 (4.5) 0.0027 5.1 (2.7) 9.6 (5.2) 0.0039 5.1 (3.3) 6.5 (3.4) 0.2156 0.9745 0.0820 0.0588 
HOMA index 1.1 (0.6) 1.9 (1.2) 0.0003 1.2 (0.7) 2.5 (1.4) 0.0031 1.0 (0.6) 1.5 (0.9) 0.0394 0.4455 0.0411 0.0568 
Matsuda 
index 
9.6 (4.9) 5.8 (3.1) 0.0044 9.6 (5.6) 4.2 (1.3) 0.0031 9.6 (4.4) 7.1 (3.6) 0.1745 0.9555 0.0203 0.2410 
Total 
cholesterol 
(mmol/L) 
4.3 (0.7) 4.6 (0.9) 0.1334 4.2 (0.5) 5.0 (0.8) 0.0273 4.4 (0.8) 4.4 (0.9) 0.8986 0.6084 0.0763 0.0618 
LDL 
cholesterol 
(mmol/L) 
2.5 (0.6) 3.0 (0.8) 0.0136 2.3 (0.4) 3.2 (0.9) 0.0075 2.7 (0.7) 2.8 (0.7) 0.5758 0.1416 0.1821 0.0248 
HDL 
cholesterol 
(mmol/L) 
1.6 (0.4) 1.3 (0.4) 0.0002 1.7 (0.4) 1.3 (0.5) 0.0030 1.6 (0.3) 1.3 (0.4) 0.0232 0.4724 0.8468 0.2902 
Triglycerides 
(mmol/L) 
0.9 (0.3) 1.2 (0.5) 0.0165 0.8 (0.3) 1.4 (0.6) 0.0304 0.9 (0.3) 1.0 (0.3) 0.3033 0.5838 0.0673 0.0689 
High-
sensitivity 
CRP (mg/L) 
1.8 (2.5) 3.6 (5.7) 0.0580 1.9 (2.6) 5.2 (7.3) 0.0381 1.8 (2.5) 1.9 (2.4) 0.9346 0.9721 0.2152 0.0639 
Physical 
activity index 
8.6 (1.5) 7.9 (1.4) 0.0119 8.8 (1.6) 7.6 (1.1) 0.0212 8.5 (1.4) 8.1 (1.6) 0.2350 0.5609 0.4455 0.2254 
Alcohol 
intake 
(dose/week) 
5.4 
(10.0) 
9.0 (8.8) 0.0961 3.8 (2.8) 11.0 (9.8) 0.0209 
7.2 
(14.4) 
6.7 (7.5) 0.8631 0.4754 0.2972 0.0557 
Energy intake 
(kcal/day) 
2126.3 
(540.2) 
2181.1 
(577.1) 
0.6900 
2070.3 
(643.4) 
2258.4 
(540.1) 
0.4386 
2170.3 
(464.3) 
2120.3 
(617.6) 
0.7610 0.5825 0.5638 0.8549 
a Unpaired t-tests were used for computing comparisons between liver fat discordant and concordant pairs (leaner vs leaner, heavier vs heavier and of 
within-pair differences). 
b Chi2 test was used to test the sex difference between liver fat discordant vs. concordant groups. 
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c Paired t-tests were used for computing comparisons of leaner and heavier co-twins within twin pairs. 
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Table 2. The 75 significantly altered proteins in the plasma proteomics between leaner and heavier BMI-discordant monozygotic co-twins (n= 26 twin pairs). 
Data derived from Uniprot. Proteins that are selected for correlation analysis are indicated in bold. 
Gene name Accession Protein description Molecular function Biological process 
Log Fold 
Change 
p value 
adj p 
value 
KRT87P A6NCN2 Putative keratin-87 protein structural molecule activity 
 
0.51 0.041 0.28 
HLA-DOA P06340 
HLA class II histocompatibility 
antigen 
MHC class II receptor activity Immune response 0.34 0.006 0.10 
DLG2 Q15700 Disks large homolog 2 kinase binding 
 
0.33 0.004 0.10 
GOLGA3 Q08378 Golgin subfamily A member 3 transporter activity transport, cellular localization 0.33 0.024 0.19 
EVL Q9UI08 Ena/VASP-like protein actin binding cytoskeleton remodeling 0.32 0.012 0.14 
PROZ P22891 Vitamin K-dependent  protein Z receptor binding Blood coagulation, Hemostasis 0.3 0.008 0.12 
RAE1 P78406 mRNA export factor RNA binding cell cycle 0.3 0.013 0.14 
EIF3H O15372 
Eukaryotic translation initiation factor 
3 subunit H 
RNA binding 
translational initiation, protein 
synthesis 
0.29 0.022 0.17 
F7 P08709 Coagulation factor VII receptor binding 
complement and coagulation 
cascades 
0.28 0.002 0.09 
MKS1 Q9NXB0 Meckel syndrome type 1 protein 
 
Cilium biogenesis/degradation 0.26 0.016 0.16 
ANKIB1 Q9P2G1 
Ankyrin repeat and  IBR domain-
containing protein 1 
Transferase protein polyubiquitination 0.2 0.012 0.14 
PCYOX1 Q9UHG3 Prenylcysteine oxidase 1 Oxidoreductase 
 
0.2 0.013 0.14 
TUBB4A P04350 Tubulin beta-4A chain 
structural constituent of 
cytoskeleton 
microtubule-based process 0.19 0.046 0.29 
PTGDS P41222 Prostaglandin-H2 D-isomerase fatty acid binding 
Fatty acid biosynthesis,  Fatty acid 
metabolism 
0.17 0.020 0.17 
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OTUD7B Q6GQQ9 OTU domain-containing protein 7B ubiquitin binding 
immune response, NF-kappaB 
signaling 
0.17 0.004 0.10 
LBP P18428 Lipopolysaccharide-binding protein lipopeptide binding 
immune response,inflammatory 
response 
0.16 0.001 0.09 
VPS11 Q9H270 
Vacuolar protein sorting-associated 
protein 11 homolog 
protein binding 
lysosome organization,protein 
trafficking 
0.15 0.009 0.13 
HGFAC Q04756 Hepatocyte growth factor activator 
serine-type endopeptidase 
activity 
proteolysis 0.15 0.003 0.10 
SAA1 P0DJI8 Serum amyloid A-1 protein Heparin-binding inflammatory response 0.15 0.020 0.17 
BLVRB P30043 Flavin reductase (NADPH) Oxidoreductase small molecule metabolic process 0.14 0.005 0.10 
NUP107 P57740 Nuclear pore complex protein RNA binding RNA transport, mRNA transport 0.13 0.0002 0.08 
C4B P0C0L5 Complement C4-B complement binding complement activation 0.12 0.001 0.08 
CFHR5 Q9BXR6 
Complement factor H-related protein 
5  
complement activation 0.12 0.002 0.10 
WDR19 Q8NEZ3 WD repeat-containing protein 19 
 
Cilium biogenesis/degradation 0.12 0.001 0.08 
DOCK9 Q9BZ29 Dedicator of cytokinesis protein 9 cadherin binding blood coagulation 0.12 0.017 0.16 
PIP4K2C Q8TBX8 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 gamma 
Kinase, Transferase 
inositol phosphate metabolic 
process, lipid metabolic process 
0.12 0.048 0.30 
TXNRD2 Q9NNW7 
Thioredoxin reductase 2, 
mitochondrial 
Oxidoreductase cell redox homeostasis 0.12 0.044 0.29 
FBXO22 Q8NEZ5 F-box only protein 22 
ubiquitin-protein transferase 
activity 
cellular protein catabolic process 0.12 0.001 0.09 
TINAG Q9UJW2 Tubulointerstitial nephritis antigen receptor binding Cell adhesion 0.12 0.015 0.15 
KRT82 Q9NSB4 Keratin, type II 
 
keratinization 0.11 0.007 0.12 
MED16 Q9Y2X0 
Mediator of RNA polymerase II 
transcription subunit 16 
catalytic activity Transcription regulation 0.11 0.003 0.10 
LDHA P00338 L-lactate dehydrogenase A chain Oxidoreductase oxidation-reduction process 0.1 0.047 0.30 
GTF3C4 Q9UKN8 
General transcription factor 3C 
polypeptide 4 
Transferase transcription 0.1 0.003 0.10 
HEXB P07686 Beta-hexosaminidase  subunit beta Glycosidase, Hydrolase Glycosaminoglycan degradation 0.1 0.006 0.10 
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SERPIND1 P05546 Heparin cofactor 2 heparin bnding 
blood coagulation, complement 
and coagulation cascades 
0.1 0.003 0.10 
BCHE P06276 Cholinesterase choline binding choline metabolic process 0.1 0.017 0.16 
ADAMTS12 P58397 
A disintegrin and metalloproteinase 
with thrombospondin motifs 12 
metalloendopeptidase activity 
cell migration, cell response to 
insulin 
0.09 0.003 0.10 
C1QA P02745 
Complement C1q subcomponent 
subunit A 
complement component C1q 
binding 
complement activation 0.09 0.019 0.17 
TTK P33981 Dual specificity protein kinase TTK Tyrosine-protein kinase cell division 0.09 0.048 0.30 
THBS1 P07996 Thrombospondin-1 receptor binding 
cell adhesion, platelet 
degranulation 
0.09 0.009 0.12 
SERPING1 P05155 Plasma protease C1 inhibitor Protease inhibitor complement activation 0.09 0.026 0.20 
MASP1 P48740 
Mannan-binding lectin serine 
protease 1 
Hydrolase complement activation 0.09 0.010 0.13 
PTGR2 Q8N8N7 Prostaglandin reductase 2 catalytic activity prostaglandin metabolic process 0.09 0.043 0.29 
APOB P04114 Apolipoprotein B-100 cholesterol transporter activity 
Regulation of plasma, lipoprotein 
level, lipid homeostasis 
0.09 0.001 0.08 
CFH P08603 Complement factor H 
 
complement activation 0.08 0.008 0.12 
CFI P05156 Complement factor I complement binding complement activation 0.08 0.005 0.10 
IZUMO3 Q5VZ72 Izumo sperm-egg fusion protein 3 
protein homodimerization 
activity  
0.08 0.005 0.10 
S100A9 P06702 Protein S100-A9 receptor binding inflammatory response 0.08 0.011 0.14 
C3 P01024 Complement C3 receptor binding complement activation 0.07 0.002 0.09 
NUP210L Q5VU65 
Nuclear pore membrane glycoprotein 
210-like  
cell development 0.07 0.049 0.30 
C8B P07358 
Complement component C8 beta 
chain 
protein complex binding complement activation 0.06 0.033 0.23 
THOC3 Q96J01 THO complex subunit 3 RNA binding RNA transport 0.06 0.045 0.29 
C8G P07360 
Complement component C8 gamma 
chain 
complement binding complement activation 0.05 0.045 0.29 
POTEI P0CG38 POTE ankyrin domain family member I ion binding retina homeostasis 0.05 0.022 0.17 
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VTN P04004 Vitronectin Heparin-binding Cell adhesion 0.05 0.031 0.23 
SERPINF1 P36955 Pigment epithelium-derived factor 
serine-type endopeptidase 
inhibitor activity 
cellular component organization 0.05 0.015 0.15 
APOD P05090 Apolipoprotein D cholesterol binding lipid transport -0.07 0.011 0.14 
LIPH Q8WWY8 Lipase member H phospholipase activity lipid catabolic process -0.11 0.004 0.10 
PLGLA Q15195 Plasminogen-like protein A Protein binding 
 
-0.12 0.019 0.16 
CCDC102B Q68D86 
Coiled-coil domain-containing protein 
102B   
-0.12 0.018 0.16 
LRRC9 Q6ZRR7 
Leucine-rich repeat-containing 
protein 9  
multicellular organismal 
homeostasis 
-0.13 0.033 0.23 
SHBG P04278 Sex hormone-binding globulin Hormone binding Regulates the plasma -0.17 0.018 0.16 
ZNF778 P60409 Zinc finger protein 778 DNA binding, Metal ion binding Transcription regulation -0.19 0.006 0.10 
RNF112 Q9ULX5 RING finger protein 112 GTPase activity Cell cycle -0.19 0.026 0.20 
GAK O14976 Cyclin-G-associated kinase 
Nucleotide-binding,Kinase 
activity 
Cell cycle -0.19 0.027 0.20 
IGJ P01591 Immunoglobulin J chain receptor binding receptor binding -0.2 0.011 0.14 
ANAPC4 Q9UJX5 
Anaphase-promoting complex subunit 
4 
protein phosphatase binding cell cycle -0.27 0.008 0.12 
PKM P14618 Pyruvate kinase PKM kinase activity Metabolic pathways -0.27 0.017 0.16 
DNASE1L1 P49184 Deoxyribonuclease-1-like 1 DNA binding 
DNA metabolic process, DNA 
binding 
-0.27 0.009 0.12 
CROCC Q5TZA2 Rootletin Actin binding, Protein binding 
Centrosome cycle, cell cycle, 
Cilium biogenesis 
-0.28 0.012 0.14 
IFT43 Q96FT9 Intraflagellar transport protein 43 
 
Cilium biogenesis -0.31 0.006 0.10 
UFL1 O94874 E3 UFM1-protein ligase 1 ligase activity Ubiquitin mediated proteolysis -0.34 0.004 0.10 
IGKC P01834 Immunoglobulin kappa constant antigen binding complement activation -0.36 0.050 0.30 
SH2D3A Q9BRG2 SH2 domain-containing protein 3A 
guanyl-nucleotide exchange 
factor activity 
JNK cascade, protein targeting to 
nucleus 
-0.43 0.004 0.10 
GALNT6 Q8NCL4 Polypeptide N-acetylgalactosaminyl N- protein glycosylation -0.46 0.030 0.22 
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transferase 6 acetylgalactosaminyltransferase 
activity 
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Figures legends 
Figure 1. A) *Venn diagram of significantly altered proteins in liver fat discordant and concordant 
monozygotic twins’ plasma. **Oliveros, J.C. (2007) VENNY.  An interactive tool for comparing lists 
with Venn Diagrams. http://bioinfogp.cnb.csic.es/tools/venny/index.html]. B) Logarithmic fold-
changes (heavier co-twins vs leaner co-twins) for the 5 common proteins in BMI-discordant, liver fat 
discordant and liver fat concordant subgroups. *p<0.05, **p<0.01, ***p<0.001. APOB: 
apolipoprotein B100, C4B: complement c4b, CFHR5: complement factor H-related protein 5, F7: 
coagulation factor VII, NUP 107: nuclear pore complex protein Nup107. 
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Figure 2. Pathway analyses of the 75 significantly altered proteins in heavy vs lean comparison of all 
BMI-discordant monozygotic twins’ plasma (n=26 twin pairs). A) Top 5 significantly enriched 
biological process according to DAVID. B) Top 5 significantly enriched canonical pathway according 
to IPA. C) Top 5 significantly enriched biological processes according to STRING. 
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Figure 3. Network of 75 significantly altered proteins in lean and heavy BMI-discordant monozygotic 
twins’ plasma (n=26 twin pairs). Top scoring pathways derived from STRING are highlighted: 
complement activation (red nodes) and regulation of inflammatory response (blue nodes). Local 
coefficient clustering: 0.411, PPI enrichment p value: 7.86e-09, expected number of edges: 29, 
number of edges: 64 (this indicates that our proteins have more interactions among themselves than 
what would be expected for a random set of proteins of similar size). The thickness of the line 
between nodes indicates the strength of data support. Disconnected nodes are removed. Data 
derived from STRING ver. 10.5 (http://string-db.org). 
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Figure 4. The correlations of the complement and inflammatory response related proteins with the 
adiposity and metabolic measurements in monozygotic twin individuals (n= 52). Proteins are 
selected due to their molecular function derived from Uniprot. BMI: Body mass index, Sc fat: 
subcutaneous fat, Ia fat: intra-abdominal fat, HOMA: The Homeostasis Model Assessment, LDL: Low 
density lipoprotein, HDL: High density lipoprotein.  *p < 0.05 , **p < 0.01, *** p < 0.001 (after 
multiple correction).  
 
  
www.clinical.proteomics-journal.com Page 26 Proteomics - Clinical Applications 
 
 
This article is protected by copyright. All rights reserved. 
26 
 
 
Figure 5. The complement cascade protein profile in plasma in monozygotic twin individuals (n= 52). 
Proteins that are upregulated in heavier co-twins are indicated with red. 
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Supplementary Figures and tables legends 
Figure S1. Liver fat content measured by magnetic resonance spectroscopy in 26 monozygotic BMI-
discordant pairs (BMI difference> 3 kg/m2).  12 pairs were grouped as liver fat discordant and 14 
pairs as liver fat concordant. 
Figure S2. Biological pathway analysis of significantly expressed proteins in the lean vs. heavy co-
twin comparison of liver fat discordant (n = 12 twin pairs) and liver fat concordant (n = 14 twin pairs) 
BMI-discordant monozygotic twin pair subgroups. Top significantly enriched biological process based 
on STRING, DAVID and IPA analysis.  
Table S1-S4. Differentially expressed plasma proteins between the lean and heavy co-twins in liver 
fat discordant (n=12 twin pairs) and liver fat concordant (n=14 twin pairs) monozygotic twin pair 
subgroups. 
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